Lupin, a global pharmaceutical company, appointed Abdelaziz Toumi as the CEO of its new subsidiary, Lupin Manufacturing Solutions (LMS). LMS focuses on the development and sales of active pharmaceutical ingredients (APIs) and is expanding its contract development and manufacturing operations (CDMO) business.
Nilesh Gupta, Lupin’s Managing Director stated, “We are thrilled to have Abdel join our team. His extensive knowledge and experience in the API CDMO industry will be crucial in establishing LMS as a reliable and preferred partner for our global clientele”.
Toumi, who has over 20 years of experience in the biotech, pharma, and CDMO sectors across Europe, North America, and Asia, has held leadership roles at Bayer, Merck, Catalent, Lonza, and KBI Biopharma, where he was instrumental in driving growth, innovation, and operational excellence. As reported by businessline, based in Switzerland, Toumi will also spend significant time in India.
